Aims/hypothesis We studied the role of protein degradation pathways in the regulation of insulin production and secretion and hypothesised that autophagy regulates proinsulin degradation, thereby modulating beta cell function. Methods Proinsulin localisation in autophagosomes was demonstrated by confocal and electron microscopy. Autophagy was inhibited by knockdown of autophagyrelated (ATG) proteins and using the H + -ATPase inhibitor bafilomycin-A1. Proinsulin and insulin content and secretion were assessed in static incubations by ELISA and RIA.
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Introduction
Orci et al showed three decades ago that beta cell insulin stores are regulated by crinophagy: granules fuse directly with large vacuolar lysosomes to generate crinophagic bodies, where granule contents are degraded [1] . Insulin may also reach lysosomes via autophagosomes that engulf cytosolic components containing secretory granules (macroautophagy), or by lysosomal engulfment of a single granule (microautophagy). It was recently reported that, in contrast to most mammalian cells, in beta cells, starvation induced lysosomal degradation of nascent insulin granules triggering lysosomal recruitment and activation of mechanistic target of rapamycin, complex 1 (mTORC1), thereby suppressing autophagy [2] . This would reduce insulin secretion in fasting; indeed, stimulation of autophagy enhanced secretion in starved beta cells. Starvation is an extreme situation; therefore, the relevance of these findings for beta cell physiology is unclear. The stimulated beta cell confronts a high protein burden as proinsulin biosynthesis rates reach 10 6 molecules/min, ∼50% of total protein synthesis [3] . Proinsulin rapidly enters the endoplasmic reticulum (ER) and undergoes oxidative folding. Misfolded proinsulin may be degraded via a process called ER-associated degradation (ERAD), which includes translocation to the cytosolic side of the ER membrane, followed by ubiquitination and delivery to proteasomes for degradation [4] . Properly folded proinsulin is transported to the cis-Golgi, then moves forward between multiple cisternae to the transGolgi network (TGN), where cisternae disintegrate to produce carriers that convey proteins to the plasma membrane, secretory granules, endosomes and lysosomes [5] .
Autophagy directs cytoplasmic components to lysosomes for degradation [6 ] . Double-membrane vesicles (autophagosomes) sequester cytosolic constituents, including misfolded proteins and damaged organelles, then fuse with lysosomes where the material is degraded and recycled. This pathway is tightly regulated by multiple proteins encoded by autophagy genes [7] [8] [9] . Beta cell Atg7 −/− mice exhibit islet degeneration, impaired insulin secretion and glucose intolerance, indicating that autophagy is essential for beta cell wellbeing [10, 11] . Alterations in autophagy have been described in animal models of diabetes and in beta cells from type 2 diabetic patients [12, 13] . Beyond ubiquitous roles, autophagy also regulates tissue-specific functions [12] . Herein, we studied the regulation of beta cell insulin-like peptides (ILPs) by autophagy and its effects on insulin secretion.
Methods
Islet isolation, cell culture and reagents Pancreases were obtained from 16-week-old beta cell Atg7 −/− mice; fed blood glucose levels were ∼12 mmol/l [14] . Islets were isolated from C57BL6 mice by collagenase injection to the bile duct. Animal use was approved by the Institutional Animal Care and Use Committee of Hebrew University. INS-1E and BON-1 cell lines were grown as previously described [15, 16] . Additional information regarding the strain of mice and the sources of cell lines and human islets is provided in electronic supplementary material (ESM) Methods. Bafilomycin-A1, MG132, lactacystin, brefeldin-A, trehalose and diazoxide were obtained from Sigma-Aldrich (Rehovot, Israel), trans-activator of transcription (Tat)-scrambled and Tat-beclin-1 were from Merck Millipore (Billerica, MA, USA).
RNA interference causing protein knockdown INS-1E cells were transfected with small interfering (si)RNA or scrambled siRNA using Jetprime transfection reagent (Polyplus Transfection, Illkirch-Graffenstaden, France). Specific anti-rat Atg5 and Atg7 siRNA smartpool sequences were ordered from Dharmacon (Lafayette, LA, USA). Cells were harvested 48 h following transfection.
Immunofluorescence Paraffin sections were rehydrated and antigens retrieved. The antibodies used are detailed in ESM Methods.
Live cell imaging A Zeiss LSM-710 confocal microscope with an incubator (37°C and 5% CO 2 ) was used (Carl Zeiss, Oberkochen, Germany). Cells were transfected with the following constructs: Lamp1-egfp [17] , Lc3 (also known as Map1lc3a)-mCherry [17] , p62 (also known as Sqstm1)-mCherry [18] , B4galt1-mTurqoise2 (mTurqoise-Golgi) (plasmid number 36205; Addgene, Cambridge, MA, USA) [19] , wild-type (WT) proinsulin-egfp, WT proinsulin-mCherry, Akita proinsulin-egfp [20] and G(B23)V proinsulin-egfp [21] . See ESM Methods for further details.
Immunogold electron microscopy Mouse pancreases were stained with primary polyclonal guinea pig anti-mouse (pro)insulin (1:200, Dako) and secondary donkey antiguinea pig gold conjugate (Jackson ImmunoResearch). See ESM Methods for further details.
Western blotting Protein levels were assessed using antibodies against different autophagy proteins, enhanced green fluorescent protein (eGFP) and chromogranin A (CgA). See ESM Methods for further details.
Insulin, proinsulin and CgA content and secretion Insulin and CgA response to secretagogues were evaluated by static incubations, followed by cell extraction and measurements of proinsulin and insulin or CgA in extracts and the medium. See ESM Methods.
Oxygen consumption Oxygen consumption was measured in INS-1E cells using V7 plates in a XF24 respirometer (Seahorse Bioscience, Billerica, MA, USA) as described previously [22] . See ESM Methods for further details. 
Statistical analysis

Results
Proinsulin degradation by lysosomes INS-1E beta cells and mouse or human islets were incubated for 1-2 h with bafilomycin-A1, an established vacuolar H + -ATPase inhibitor. Surprisingly, short-term (≤120 min) treatment with 100 nmol/l bafilomycin-A1 increased the steady-state proinsulin content both in INS-1E cells and islets (Fig. 1a-c) . In mouse islets, proinsulin was increased by ∼50%, accompanied by increased total ILP content. In INS-1E cells and human islets there was a smaller increase in proinsulin, without affecting insulin content (Fig. 1a-f ). Proinsulin increase after short-term bafilomycin-A1 treatment was unexpected considering its abundance in beta cells, suggesting that substantial amounts of proinsulin are degraded in lysosomes. This cannot be explained by inhibition of secretion, as 2 h treatment of islets with bafilomycin-A1 at 11.1 mmol/l glucose did not decrease insulin or proinsulin secretion. Furthermore, inhibition of proinsulin secretion by diazoxide failed to increase islet proinsulin (ESM Fig. 1 ). In mouse islets, bafilomycin-A1 similarly increased proinsulin content at 5.5-22 mmol/l glucose, suggesting that lysosomal degradation of proinsulin is not affected by ambient glucose (ESM Fig. 2 ). Bafilomycin-A1 increased both proinsulin and insulin; thus, the effect on proinsulin content cannot be explained by perturbation of proinsulin conversion to insulin.
To gain mechanistic information, we used proinsulin constructs tagged with various fluorescent markers. Enhanced GFP or mCherry was inserted into the C-peptide domain of proinsulin [20] . This enabled monitoring of proinsulin and C-peptide levels without interference from fully processed insulin, devoid of tag. We studied the effects of bafilomycin-A1 and proteasome inhibitors (MG-132 and lactacystin) on proinsulin levels and degradation in INS-1E cells (Fig. 1g-j) . Bafilomycin-A1 increased the proinsulin-eGFP level, thus adequately reflecting changes in proinsulin concentrations measured by ELISA. Proteasome inhibitors had a small effect on proinsulin in INS-1E cells, consistently smaller than that of bafilomycin-A1 (Fig. 1g, h ). Treatment of islets with lactacystin for 2 h was associated with decreased, rather than increased, proinsulin content (ESM Fig. 3 ), further suggesting that lysosomes are the main regulators of proinsulin degradation. To exclude interference with changes in translation rate, beta cells were treated with the protein biosynthesis inhibitor cycloheximide; bafilomycin-A1 again increased proinsulin at 2 and 4 h, while there was a small, non-significant effect of lactacystin (Fig. 1i, j) . Bafilomycin-A1 may impair the acidification of young secretory granules, where proinsulin is processed to insulin; this may inhibit proinsulin-to-insulin conversion, thereby increasing proinsulin content. To exclude this, we analysed the bafilomycin-A1 effect on C-peptideeGFP expression in INS-1E cells treated with cycloheximide ( Fig. 1i, ESM Fig. 4 ). Bafilomycin-A1 induced a parallel increase in proinsulin-eGFP and C-peptide-eGFP, indicating that proinsulin conversion to insulin was not impaired.
Collectively, these findings indicate that the bafilomycin-A1 effect on beta cell proinsulin is mediated via inhibition of protein degradation, rather than impairment of proinsulin processing or insulin secretion, and that lysosomal degradation of proinsulin dominates degradation by the proteasome.
Lysosomal degradation of proinsulin is via autophagy Proteins may reach the lysosome through multiple pathways including, but not limited to, autophagy. We have previously shown that in beta cell lines and islets autophagic flux is rapid, evident by high turnover of light chain microtubule-associated protein 3 (LC3), vesicle-associated form (LC3-ΙΙ) [23] . Consistently, bafilomycin-A1, but not the proteasome inhibitor, robustly increased LC3-ΙΙ, along with proinsulin-eGFP (and C-peptide-eGFP) expression (ESM Fig. 5 ). To clarify whether proinsulin is delivered to lysosomes via autophagy, we performed imaging studies and knocked down autophagy proteins. INS-1E cells were co-transfected with mCherry-or eGFP-labelled proinsulin and the (auto)lysosome markers Lamp1-egfp or p62 -mCherry and then treated with or without bafilomycin-A1 (Fig. 2a, b) . At baseline, proinsulin-mCherry and lysosomal-associated membrane protein 1 (LAMP1)-eGFP colocalisation was relatively scant. Inhibition of lysosome activity resulted in accumulation of proinsulin-mCherry in lysosomes at 30 min, suggesting that proinsulin turnover is rapid.
We have shown that the mTORC1 inhibitor rapamycin stimulates autophagy in beta cells [23] . Rapamycin increased the localisation of proinsulin-eGFP/mCherry in p62 + vesicles (Fig. 2c, d) ; this was associated with a small, borderline significant, decrease in proinsulin level (Fig. 2e) . The autophagy stimulators Tat-beclin1 and trehalose also decreased proinsulin level in INS-1E cells (Fig. 2f, g ). Together, these findings suggest that proinsulin is assigned for lysosomal degradation through autophagy.
Autophagosome maturation involves conversion of LC3, soluble cytosolic form (LC3-І) to LC3-ІI, which appears as dots (punctae) on fluorescence microscopy. Proteins destined proinsulin-eGFP and B4GALT1-mTurquoise, and analysed by confocal microscopy. LC3-mCherry colocalised with proinsulin-eGFP and B4GALT1-mTurqoise in autophagic punctae (Fig. 2h) , indicating that proinsulin is present in autophagosomes containing TGN-derived membrane proteins. Treatment with brefeldin-A, which prevents protein transport from ER to Golgi, abolished the lysosomal degradation of proinsulin (ESM Fig. 6 ), further suggesting that proinsulin channelling for autophagic degradation occurs downstream to the ER. Autophagy related (ATG)5 and ATG7 are required for autophagosome elongation and maturation [7] . Partial depletion of both ATGs impaired autophagy, as shown by decreased LC3-ІІ expression (Fig. 3a-e) . This resulted in an ∼50% increase in beta cell proinsulin at 3.3-22.2 mmol/l glucose, without affecting insulin content (ESM Fig. 7, Fig. 3f-h ). This cannot be explained by inhibition of proinsulin secretion, as increased proinsulin content in autophagy-deficient INS-1E cells was accompanied by increased proinsulin secretion (see Fig. 4) .
Together, our findings show that proinsulin is assigned for lysosomal degradation through autophagy, and suggest that this occurs at the TGN.
Effects of inhibiting autophagy on proinsulin and insulin secretion Autophagy deficiency induced by ATG5/7 knockdown did not affect basal insulin secretion. By contrast, it increased glucose-stimulated insulin secretion (Fig. 4a) , especially at submaximal glucose (11.1 mmol/l). ATG5/7 knockdown increased in parallel insulin and proinsulin secretion in response to glucose, plasma membrane depolarisation by KCl and the sulfonylurea glibenclamide (Fig. 4a-c) . In autophagydeficient cells, the relative increase in proinsulin secretion exceeded that of insulin (Fig. 4d) , suggesting that processing of rescued proinsulin to insulin was incomplete. ATG5/7 knockdown did not affect mitochondrial respiration (ESM Fig. 8 ). Inhibition of autophagy increased insulin secretion by KCl and glibenclamide, further suggesting that its effects on secretion are not mediated via modulation of mitochondrial metabolism. Consistent with the hypothesis that autophagy inhibits insulin secretion, we found that Tat-beclin1 decreased glucose-stimulated insulin secretion (Fig. 4e) . Trehalose also decreased insulin secretion, although the difference was not significant (Fig. 4f) . Collectively, our findings show that autophagy restrains insulin secretion; its inhibition enables proinsulin accumulation in secretory granules, followed by processing and increased secretion in response to stimuli.
Regulation of proinsulin by autophagy in vivo The intracellular localisation of ILP was studied by electron microscopy (EM). Pancreatic sections were stained by immunogold labelling for insulin using an antibody that recognises all ILPs, including proinsulin. As expected, ILPs were abundant in secretory granules and were not observed in non-beta cells (ESM Fig. 9 ), indicating specific staining. ILP was observed in lysosomes containing single secretory granules suggestive of microautophagy, and in crinophagic bodies containing single secretory granules (Fig. 5a) , as well as multigranular bodies, which contain secretory granule core-like material (not shown). In addition, we observed double-membrane structures, likely autophagosomes, containing dispersed ILPs, not in the form of insulin granules (Fig. 5a) . To further show that proinsulin is regulated by autophagy in vivo, we immunostained pancreatic sections from beta-Atg7 −/− mice for proinsulin and for p62. Life-long ATG7 deficiency results in beta cell degeneration, insulin deficiency and glucose intolerance. Beta-Atg7 −/− mice were depleted of insulin and contained p62 + ubiquitinated protein aggregates [10, 11] . We found that islets were also depleted of proinsulin (Fig. 5b) ; despite this, a DAPI Proinsulin P62 Atg7 +/+ and Atg7 −/− mice stained for proinsulin and p62. Scale bars, 20 μm proinsulin was found in part of the p62 + aggregates, suggesting that it serves as substrate for autophagy also in vivo.
Autophagy regulates CgA in endocrine cells We studied whether autophagy also regulates other residents of the secretory pathway. CgA belongs to a family of large acidic secretory proteins found in most neuroendocrine tissues, including beta cells, stored with peptide hormones in secretory vesicles [25] . CgA is a large precursor peptide that, like proinsulin, undergoes proteolytic processing during its routing to and storage in secretory vesicles [26] . Inhibition of autophagy by ATG5/7 knockdown or treatment with bafilomycin-A1 markedly increased CgA expression in INS-1 beta cells, as well as in human pancreatic neuroendocrine cells (BON-1) , whereas inhibition of proteasomal degradation had no effect (Fig. 6a-d) . Increased CgA expression in BON-1 cells was accompanied by a small but significant increase in CgA secretion (Fig. 6e) , thus resembling proinsulin regulation by autophagy.
Irreparably mutated forms of proinsulin are refractory to autophagic degradation The Akita proinsulin is trapped in the ER [23, 27] . Akita proinsulin labelled with eGFP was transfected to INS-1E cells and its assignment for autophagic degradation analysed by confocal microscopy and western blotting (Fig. 7) . Intriguingly, Akita proinsulin was not found in autophagic punctae, including in cells in which autophagy was stimulated by rapamycin. Consistently, Akita proinsulin was not degraded in lysosomes, as shown by the failure of bafilomycin-A1 to increase Akita proinsulin-eGFP expression (Fig. 7b-e) . The G(B23)V proinsulin mutated form also generates ER stress; however, a small portion of this form may reach secretory granules [21] . In contrast to WT cells, bafilomycin-A1 failed to increase G(B23)V proinsulin expression; similarly, inhibition of the proteasome did not affect the steady-state proinsulin content (Fig. 7d, e) .
Collectively, our findings show that irreparably mutated forms of proinsulin are trapped in the ER, are not transported to autophagosomes and are refractory to lysosomal degradation.
Discussion
Our study suggests a previously unappreciated role for autophagy in beta cell proinsulin handling and insulin secretion. We show that a substantial amount of proinsulin is rapidly delivered to autophagosomes and directed to lysosomal degradation. Quantitatively, the impact of this pathway on proinsulin level is robust, as short-term inhibition of lysosomal degradation increased steady-state proinsulin content quite significantly. This was entirely unexpected, considering the background abundance of proinsulin in the beta cell. Indeed, while stimulation of beta cells with high glucose may induce up to a 25-fold increase in proinsulin biosynthesis [3] , the steady-state proinsulin level nevertheless remains unchanged. Thus, the increase in proinsulin content following inhibition of lysosomal degradation shown here is indeed striking. Bafilomycin-A1 increased proinsulin by inhibiting its degradation; the changes in steady-state proinsulin level were not due to inhibition of its conversion to insulin or to reduction of exocytosis. Bafilomycin-A1 may indeed affect vesicular pH, thereby impairing proinsulin processing and secretion; however, such alterations cannot account for the observed changes in proinsulin level. Bafilomycin-A1 did not affect cumulative insulin secretion; moreover, inhibition of insulin secretion by diazoxide failed to increase proinsulin content. Increased proinsulin in bafilomycin-A1-treated cells and mouse islets was accompanied by a parallel increase in C-peptide, indicating that proinsulin was converted to insulin. Most importantly, genetic disruption of autophagy similarly increased proinsulin content, further suggesting that inhibition of lysosomal degradation is the main cause of the increase in beta cell proinsulin.
Several lines of evidence suggest that the canonical macroautophagy is the central degradation mechanism regulating proinsulin: EM revealed dispersed, non-granular ILP located in autophagosome-like structures and confocal microscopy showed proinsulin localisation in LC3 + and p62 + punctae and in protein aggregates that appear in autophagydeficient beta-Atg7 knockout mice. Moreover, knockdown of key ATGs increased, whereas genetic and pharmacologic stimulators of autophagy (Tat-beclin 1, rapamycin and trehalose) decreased, proinsulin content. CgA, a precursor of secretory hormones in different neuroendocrine cells, is also robustly degraded by autophagy, suggesting that autophagy is a key regulatory pathway of hormone precursors in endocrine cells. It has previously been shown that certain residents of the secretory pathway in beta cells, e.g. pancreatic prohormone convertases, are not degraded by autophagy [28] , suggesting that the autophagic degradation of complex peptides like proinsulin and CgA is a selective process.
The degradation of insulin and proinsulin by lysosomes appears dissimilar. Insulin granule degradation is mainly mediated via microautophagy and crinophagy, whereas proinsulin degradation is mediated via macroautophagy. Pharmacological and genetic inhibition of autophagy increased proinsulin content without affecting insulin, hence the importance of lysosomal proinsulin degradation greatly outweighs that of insulin. It has recently been suggested that insulin granules may undergo autophagy-independent lysosomal degradation to keep insulin secretion low and avoid hypoglycaemia in the fasting state [2] . Stimulation of autophagy by Tat-beclin1 increased insulin secretion under fasting conditions and in response to high glucose; however, the mechanisms involved are not clear. We found that in beta cells autophagic flux is rapid, rather than being suppressed, both in KRB-HEPES and rich medium. Strikingly, increasing the proinsulin content by genetic disruption of autophagy was associated with a parallel increase in proinsulin and insulin secretion, whereas stimulation of autophagy inhibited insulin secretion, indicating that autophagy restrains, rather than stimulates, secretion. Our findings are in agreement with Pearson et al, who also found that inhibiting autophagy enhanced insulin secretion [29] . This may suggest that inhibition of proinsulin export to autophagosomes extends proinsulin residency in the secretory pathway followed by packaging into secretory granules, processing and secretion.
Intriguingly, the Akita mutated form of proinsulin, which is trapped in the ER and cannot be delivered to the Golgi and secretory granules [20, 30, 31] , was resistant to lysosomal degradation; this may suggest that ER exit to the secretory pathway is essential for proinsulin degradation via autophagy to occur. Indeed, treatment with brefeldin-A, which prevents ER exit, abolished the lysosomal degradation of WT proinsulin. We found that proinsulin-containing autophagosomes expressed the TGN protein B4GALT1, hence we suggest that proinsulin delivery to autophagosomes takes place at the TGN. Further studies are required to uncover the precise location and the molecular mechanisms of selective proinsulin delivery to autophagosomes.
What is the biological rationale for proinsulin degradation by autophagy? In endocrine cells such as beta cells, intense hormone biosynthesis and flow through the ER-Golgi, along with highly dynamic changes in secretion, rationalises the need for an effective post-ER degradation pathway that clears surplus hormone precursors in the resting state. It may be speculated that this may function as a 'buffering' system aimed to prevent cargo overload at the Golgi, which may saturate the convertases with consequent prohormone oversecretion. Hence, autophagy can be viewed as a secretory pathway checkpoint that regulates hormone secretion.
The importance of autophagy for quality control is demonstrated by the fact that its disruption results in beta cell stress, cellular degeneration and impaired insulin secretion [10, 11] , which may promote the progression from insulin resistance to diabetes [14] . Recently, it was shown that impaired autophagy led to accumulation of human islet amyloid polypeptide (hIAPP) and exacerbated hIAPP-induced beta cell toxicity [32] [33] [34] . Hence, inhibiting autophagy might be a doubleedged sword: increasing insulin secretion in the short term, at the expense of ER stress and consequent beta cell degeneration and insulin deficiency in the long term.
Overall, we show that autophagy is a post-ER pathway regulating proinsulin levels and insulin secretion. The Golgi network may function as a bifurcation node determining proinsulin fate in the beta cell, assigning it either for further processing and secretion, or for degradation. Reduction of autophagy increases proinsulin retention in the secretory pathway, resulting in enhanced insulin secretion. The autophagic degradation of WT proinsulin has important pathophysiological implications for the development of insulin deficiency in diabetes and highlights the potential for novel therapeutic strategies to manipulate proinsulin clearance as a means to enhance insulin secretion in type 2 diabetes.
